Recombinant multivalent vaccines

Abstract

The present invention relates to a recombinant multivalent vaccine. The recombinant multivalent vaccine comprises a recombinant protein, which comprises, from the N-terminus to the C-terminus, a first antigenic peptide, an N-polypeptide (SEQ ID NO.1), a second antigenic peptide, a C-polypeptide (SEQ ID NO.3) and a third antigenic peptide, the N-polypeptide and the C-polypeptide being polypeptides formed with an intramolecular scaffold, which supports and stabilizes the intramolecular scaffold NC of the conformation of the first antigenic peptide, the second antigenic peptide and the third antigenic peptide. The present invention provides recombinant multivalent vaccines 3Ro-NC (SEQ ID NO.17) and 3Rs-NC (SEQ ID NO.19) against SARS-CoV-2 mutant strains. The present invention can provide protection against Omicron infection in the upper and lower respiratory tracts by using 3Ro-NC and KFD as a prophylactic mucosal SARS-CoV-2 vaccine.